{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T22:18:07Z","timestamp":1755037087857,"version":"3.41.2"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic granulomatous disease (CGD) is an inborn error of immunity (IEI) disorder that results from defects in the respiratory burst activity in phagocytes, leading to the inability to kill bacterial and fungal microorganisms. CGD patients usually have a high incidence of morbidity such as infections and autoinflammatory diseases and a high mortality rate. Allogeneic bone marrow transplantation (BMT) is the only definitive cure for patients who suffer from CGD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We report the first transplant case of chronic granulomatous disease in Vietnam. A 25-month-old boy with X-linked CGD underwent bone marrow transplantation from his 5-year-old, full-matched human leukocyte antigen (HLA)-carrier sibling after myeloablative conditioning regimen with busulfan 5.1 mg\/kg\/day for 4 days, fludarabine 30 mg\/m<jats:sup>2<\/jats:sup>\/day for 5 days, and rATG (Grafalon-Fresenius) 10 mg\/kg\/day for 4 days. Neutrophil was engrafted on day 13 posttransplant, donor chimerism was 100% on day 30 with the dihydrorhodamine-1,2,3 (DHR 123) flow cytometric assay test that reached 38% of the normal 45 days posttransplant. Five months after transplant, the patient was free of infection with stable DHR 123 assay at 37%, and donor chimerism remained 100%. No sign of a graft-versus-host disease had been observed posttransplant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We suggest that bone marrow transplantation is a safe and effectual cure for CGD patients, especially for patients with HLA-identical siblings.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1134852","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T12:58:48Z","timestamp":1681995528000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The first successful bone marrow transplantation in Vietnam for a young Vietnamese boy with chronic granulomatous disease: a case report"],"prefix":"10.3389","volume":"14","author":[{"given":"Binh","family":"Nguyen-Thanh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le","family":"Nguyen-Ngoc-Quynh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ha","family":"Dang-Thi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi","family":"Le-Quynh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anh","family":"Nguyen-Thi-Van","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huyen","family":"Thuc-Thanh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duong","family":"Dang-Anh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela P.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tung","family":"Cao-Viet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dien","family":"Tran-Minh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08800-x","article-title":"Chronic granulomatous disease: a comprehensive review","volume":"61","author":"Yu","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.12688\/f1000research.11789.1","article-title":"Recent advances in understanding and treating chronic granulomatous disease","volume":"6","author":"Gennery","year":"2017","journal-title":"F1000Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.iac.2010.01.003","article-title":"Hematopoietic stem cell transplantation for chronic granulomatous disease","volume":"30","author":"Seger","year":"2010","journal-title":"Immunol Allergy Clin North Am"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00107","article-title":"A novel mutation in chronic granulomatous disease: treating the family, not just the patient","volume":"7","author":"Lutzkanin","year":"2019","journal-title":"Front Pediatr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2022.06.003","article-title":"Novel mutations in unrelated Vietnamese patients with chronic granulomatous disease","volume":"533","author":"Binh","year":"2022","journal-title":"Clin Chim Acta"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0583","article-title":"Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000","volume":"100","author":"Seger","year":"2002","journal-title":"Blood."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005590","article-title":"Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults","volume":"136","author":"Chiesa","year":"2020","journal-title":"Blood."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62069-3","article-title":"Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study","volume":"383","author":"Gungor","year":"2014","journal-title":"Lancet."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(82)80017-6","article-title":"Allogeneic bone marrow transplantation for chronic granulomatous disease","volume":"101","author":"Rappeport","year":"1982","journal-title":"J Pediatr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.08.013","article-title":"A single-center experience comparing alemtuzumab, fludarabine, and melphalan reduced-intensity conditioning with myeloablative busulfan, cyclophosphamide, and antithymocyte globulin for chronic granulomatous disease","volume":"22","author":"Khandelwal","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000021","article-title":"Two decades of excellent transplant survival for chronic granulomatous disease: a supraregional immunology transplant center report","volume":"133","author":"Lum","year":"2019","journal-title":"Blood."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01605","article-title":"Current perspectives and unmet needs of primary immunodeficiency care in Asia pacific","volume":"11","author":"Leung","year":"2020","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1749-6632.2011.06225.x","article-title":"Improving care, education, and research: the Asian primary immunodeficiency network","volume":"1238","author":"Lee","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01378-8","article-title":"EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity","volume":"56","author":"Lankester","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00489","article-title":"Diagnosis and treatment of VOD\/SOS after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Bonifazi","year":"2020","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0636-2","article-title":"A review of chronic granulomatous disease","volume":"34","author":"Arnold","year":"2017","journal-title":"Adv Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005234","article-title":"Chronic granulomatous disease: the European experience","volume":"4","author":"van den Berg","year":"2009","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.04.014","article-title":"Inflammatory manifestations in a single-center cohort of patients with chronic granulomatous disease","volume":"134","author":"Magnani","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318297427d","article-title":"Gastrointestinal histopathology in chronic granulomatous disease: a study of 87 patients","volume":"37","author":"Alimchandani","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1086\/520985","article-title":"Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease","volume":"45","author":"Siddiqui","year":"2007","journal-title":"Clin Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2008.03644.x","article-title":"Special article: chronic granulomatous disease in the united kingdom and Ireland: a comprehensive national patient-based registry","volume":"152","author":"Jones","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piy015","article-title":"Allogeneic hematopoietic cell transplantation for chronic granulomatous disease: controversies and state of the art","volume":"7","author":"Connelly","year":"2018","journal-title":"J Pediatr Infect Dis Soc"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16939","article-title":"Progress in treating chronic granulomatous disease","volume":"192","author":"Gennery","year":"2021","journal-title":"Br J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0281-7","article-title":"Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children","volume":"54","author":"Philippe","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"B25","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.bbmt.2009.12.094","article-title":"Low-dose busulfan\/full-dose fludarabine-based reduced-intensity conditioning in 30 high-risk paediatric and adult chronic granulomatous disease patients","volume":"46","author":"Gungor","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.04.035","article-title":"X-Linked carriers of chronic granulomatous disease: illness, lyonization, and stability","volume":"141","author":"Marciano","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B27","unstructured":""},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2431-14-129","article-title":"Clinical and mutational features of Vietnamese children with X-linked agammaglobulinemia","volume":"14","author":"Vu","year":"2014","journal-title":"BMC Pediatr"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1134852\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T12:58:50Z","timestamp":1681995530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1134852\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2023.1134852"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1134852","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"article-number":"1134852"}}